Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Talkspace. The associated price target is $9.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Rhyee has given his Buy rating due to a combination of factors tied to Talkspace’s operating momentum and outlook. He highlights that the company exceeded expectations on both revenue and adjusted EBITDA, raised its 2026 guidance above consensus, and continues to benefit from a successful pivot toward payor-channel growth, supported by strong session volume and deeper penetration of existing accounts.
He also points to the structural tailwind from payor revenue, which is growing at a near-40% annual rate with a meaningful portion coming from current clients, and expects additional directory integrations to further support utilization. In his view, the upcoming launch of the proprietary, HIPAA-compliant TalkAI agent and improved positioning within commercial LLM ecosystems provide incremental upside, justifying both the higher price target and a Buy recommendation.
According to TipRanks, Rhyee is a 4-star analyst with an average return of 2.7% and a 50.20% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Cardinal Health, Cigna, and CVS Health.
In another report released today, Needham also reiterated a Buy rating on the stock with a $6.00 price target.